Table 2 Comparison of the clinical and epidemiological characteristics of the derivation and validation cohorts

Country:

0.002

Spain

2080 (67.6%)

1048 (70.3%)

1032 (65.1%)

Other

995 (32.4%)

442 (29.7%)

553 (34.9%)

Understanding:

0.003

Good

2566 (91.7%)

1266 (90.1%)

1300 (93.3%)

Poor

232 (8.29%)

139 (9.89%)

93 (6.68%)

Living situation:

0.250

Alone

312 (10.5%)

157 (10.7%)

155 (10.3%)

Homeless or institutionalized

92 (3.10%)

54 (3.69%)

38 (2.52%)

Group

376 (12.7%)

189 (12.9%)

187 (12.4%)

Family

2191 (73.7%)

1062 (72.6%)

1129 (74.8%)

Intravenous drug use:

<0.001

No

1399 (45.5%)

872 (58.5%)

527 (33.2%)

Yes

49 (1.59%)

21 (1.41%)

28 (1.77%)

Unknown

1627 (52.9%)

597 (40.1%)

1030 (65.0%)

Age (years):

0.449

18-30

986 (32.3%)

497 (33.4%)

489 (31.3%)

31-50

1233 (40.4%)

596 (40.0%)

637 (40.8%)

>50

834 (27.3%)

397 (26.6%)

437 (28.0%)

Human immunodeficiency virus infection:

<0.001

No

2284 (74.3%)

1060 (71.1%)

1224 (77.2%)

Yes

148 (4.81%)

66 (4.43%)

82 (5.17%)

Unknown

643 (20.9%)

364 (24.4%)

279 (17.6%)

Use of directly observed treatment:

0.017

No

2626 (91.1%)

1338 (89.8%)

1288 (92.4%)

Yes

258 (8.95%)

152 (10.2%)

106 (7.60%)

Sex:

0.476

Male

1945 (64.0%)

920 (63.4%)

1025 (64.7%)

Female

1092 (36.0%)

532 (36.6%)

560 (35.3%)

Country- Healthcare

<0.001

Primary care

511 (17.1%)

268 (18.0%)

243 (16.1%)

Urgent care

1461 (48.8%)

682 (45.8%)

779 (51.7%)

Specialist

476 (15.9%)

210 (14.1%)

266 (17.7%)

Unknown'

548 (18.3%)

330 (22.1%)

218 (14.5%)

Employment:

<0.001

Disabled

98 (3.39%)

68 (4.70%)

30 (2.08%)

Employed

1781 (61.6%)

901 (62.3%)

880 (60.9%)

Unemployed

547 (18.9%)

257 (17.8%)

290 (20.1%)

Retired

464 (16.1%)

220 (15.2%)

244 (16.9%)

Previous anti-tuberculosis treatment:

0.304

No

2728 (91.5%)

1320 (91.0%)

1408 (92.1%)

Yes

252 (8.46%)

131 (9.03%)

121 (7.91%)

Lost to follow-up outcome

0.974

No

2814 (93.5%)

1332 (93.5%)

1482 (93.5%)

Yes

195 (6.48%)

92 (6.46%)

103 (6.50%)